Hoth Therapeutics (HOTH) said Friday it has filed two US provisional patent applications aimed at expanding its intellectual property portfolio and establishing an oncology-focused dermatology platform.

One patent covers the topical treatment of radiation-induced skin toxicity in oncology patients, while the second covers the dermatologic adverse effects associated with newer targeted cancer therapies, the company said.

Hoth said its patent strategy focuses on protecting the use of HT-001, a receptor antagonist, in modulating neurogenic and inflammatory pathways implicated in therapy-induced skin injury.

Hoth shares were more than 5% higher in premarket trading.